<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100518003954N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-02-14</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of ketamine and dexmedetomidine on preoperative sedation and intraoperative bleeding and analgesia during recovery</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effect of intranasal ketamin and intranasal dexmedetomedin versus placebo on sedation,bleeding,pain &amp; agitation in children undergoing adenotonsilectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-08-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>3</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/42706</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Factorial, Purpose: Treatment, Randomization description: For this purpose we will use the hexadecimal random blocks method. For this purpose, we produce six sheets of paper. On the two sheets the letter K means "Ketamin" and on the other two sheets the letter D "dexmedetomedin" and on the two sheets the letter P means Placebo. Mix the sheets together and place in a drawer. On referral to each eligible patient, one leaf was randomly drawn and assigned to one of three study groups according to this leaflet, whether K, D or P.
It should be noted that the drawn sheets will not be returned to the drawer until all six sheets have been drawn. After randomly pulling out all six sheets, all sheets will be returned to the drawer and the same operation will continue for the next six patients until the desired sample size (93 patients) is reached, Blinding description: In this study, the researcher first presents the necessary explanations to the child's father {patient's father}. In the drawer she receives from the nurse, the patient is left unaware of the chosen group. Questionnaires and surveys are carried out by the researcher to the end. The analyzer analyzes the data based solely on the three types of groups a, b, and c, and after receiving the information from the analyzer, the nurse determines the relationship between the groups at the end.</study_design>
      <phase>3</phase>
      <hc_freetext>Evaluation of the effect of ketamine or dexmedetomidine on placebo for preoperative relaxation&amp; Intraoperative hemorrhage and postoperative analgesia in patients undergoing adenotonsillectomy.</hc_freetext>
      <i_freetext>Intervention group: This study is a randomized clinical trial of children in need of elective adenotonsillectomy with ASA status I and II in Hamadan Baysat Hospital in 1397. After sufficient explanation is given to parents if they consent to participate in the informed consent study. Patients were randomly divided into three groups: dexmedetomidine (D), ketamine (k) and placebo (normal saline (NS)). Patients were given 2μg / kg of dexmodetimidine or 5mg / kg of ketamine 30 minutes before induction of anesthesia and in the control group received 5 drops of 9% normal saline with 2mg syringe when the child was present with their parents.Medications are given in both nostrils in recumbent position. Blood pressure, pulse rate, and Spo2 were measured every 15 minutes until the patient was discharged from the recovery room. Patients were treated with 1mg / kg fentanyl intravenously and anesthetized with isoflurane 20 minutes prior to anesthesia. Completion of the procedure for all patients for analgesia is 15 mg / kg of acetaminophen infused with 20 cc normal saline. Intervention group 1: Intranasal ketamine 5 mg / kg once 30 min before anesthesia • Intervention group 2: Intranasal dexmedothymidine 2 micrograms per kg 30 minutes before anesthesia • Comparison group: Normal saline intravenously Nose 4 drops once 30 minutes before anesthesia begins.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Individual data of study participants, after unidentifiable individuals, can be shared in most tables and graphs.

When:
Start data access period  6 month after printing results

To whom:
The data will be available to researchers working in academic and scientific institutions.

Conditions:
It is possible to use the data after obtaining the written consent of the researchers

Where to obtain:
Dr. Mohammad Hossein Bakhshai : bakhshaei@umsha.ac.ir 
Dr. Mohsen Zarei : drm.zarei@yahoo.com

How to obtain:
If you send an email, the data request will be answered within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohsen Zarei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bassat Hospital, Beheshti Blvd.</address>
        <city>Hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6515713834</zip>
        <telephone>+98 81 3264 0020</telephone>
        <email>drm.zarei@yahoo.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Hossein Bakhshaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Bassat Hospital, Shahid Beheshti Boulevard</address>
        <city>hamedan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6515713834</zip>
        <telephone>+98 81 3264 0021</telephone>
        <email>bakhshaei@umsha.ac.ir</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children undergoing adenotonsillectomy surgery who do not have concomitant disease.</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Drug sensitivity to ketamine or dexmedothymidine
Mental retardation
ADHD
Psychiatric drug use
History of heart, kidney, liver disease
Any pathological problems in the nose
Patients who return to the operating room due to postoperative bleeding</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: This study is a randomized clinical trial of children in need of elective adenotonsillectomy with ASA status I and II in Hamadan Baysat Hospital in 1397. After sufficient explanation is given to parents if they consent to participate in the informed consent study. Patients were randomly divided into three groups: dexmedetomidine (D), ketamine (k) and placebo (normal saline (NS)). Patients were given 2μg / kg of dexmodetimidine or 5mg / kg of ketamine 30 minutes before induction of anesthesia and in the control group received 5 drops of 9% normal saline with 2mg syringe when the child was present with their parents.Medications are given in both nostrils in recumbent position. Blood pressure, pulse rate, and Spo2 were measured every 15 minutes until the patient was discharged from the recovery room. Patients were treated with 1mg / kg fentanyl intravenously and anesthetized with isoflurane 20 minutes prior to anesthesia. Completion of the procedure for all patients for analgesia is 15 mg / kg of acetaminophen infused with 20 cc normal saline. Intervention group 1: Intranasal ketamine 5 mg / kg once 30 min before anesthesia • Intervention group 2: Intranasal dexmedothymidine 2 micrograms per kg 30 minutes before anesthesia • Comparison group: Normal saline intravenously Nose 4 drops once 30 minutes before anesthesia begins</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Relaxation before intranasal injection of ketamine or dexmedetomidine in adenotonsillectomy. Timepoint: Evaluation of sedation before adenotonsillectomy in children receiving intranasal ketamine or dexmedetomidine versus placebo 15 and 30 minutes after drug administration. Method of measurement: Questionnaire according to clinical criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Evaluation of the effect of medication on intraoperative bleeding. Timepoint: At the end of surgery. Method of measurement: Calculation of bleeding inside the suction bottle and bleeding medical gases.</sec_outcome>
      <sec_outcome>Evaluation of the effect of medication on postoperative pain and restlessness. Timepoint: Evaluation of patient pain and restlessness at 15, 30, 45 and 60 minutes after surgery in recovery. Method of measurement: Using the standard questionnaire: Children's Hospital of Eastern Ontario pain score and Pediatric Anesthesia Emergency Delirium (PAED) scal.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-09</approval_date>
        <contact_name>Ethics committee of Hamedan university of Medical sciences</contact_name>
        <contact_address>Hamedan University of Medical Sciences Hamedan Hamadan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
